Clinical Trial: A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07500207) titled 'A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)' on March 19.

Brief Summary: Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization.

The seroconversion rate of neutralizing antibodies 42 days after the first dose among seronegative participants before vaccination in each group

Study Start Date: March 04

Study Type: INTERVENTIONAL

Condition: Rabies Prevention

Intervention: BIOLOGICAL: Experimental Lyophilized Human Rabies Vaccine (Human Diploid ...